SCHEMBL744075

SCHEMBL744075

CC(=O)N(Nc1ccccc1)c1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
NAPRT Q6XQN6 1/20 0.47
HSD17B10 Q99714 1/20 0.47
TSHR P16473 2/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX5 P09917 1/20 0.44
KMT2A Q03164 4/20 0.43
MEN1 O00255 3/20 0.43
TDP1 Q9NUW8 2/20 0.42
MITF O75030 1/20 0.42
PAX8 Q06710 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPC1 O15118 3/20 0.41
TAAR1 Q96RJ0 2/20 0.41
MAPT P10636 2/20 0.41
POLB P06746 1/20 0.41
HTT P42858 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3080983 0.83 SMN1; SMN2 (0.69) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR
SCHEMBL22518481 0.82 RAB9A (0.57) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR
SCHEMBL11321854 0.81 RAB9A (0.53) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR
SCHEMBL10491015 0.80 RAB9A (0.56) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR
SCHEMBL8384059 0.80 SMN1; SMN2 (0.65) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR
SCHEMBL11856575 0.80 RAB9A (0.65) RAB9ASMN1; SMN2HSD17B10TSHRKMT2A
SCHEMBL6682364 0.80 SMN1; SMN2 (0.65) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR
SCHEMBL28834690 0.80 SMN1; SMN2 (0.65) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR
SCHEMBL9082472 0.80 SMN1; SMN2 (0.65) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR
SCHEMBL28872509 0.80 SMN1; SMN2 (0.65) RAB9ASMN1; SMN2NAPRTHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138356-B2 Chemical inhibitors of inhibitors of differentiation Angiogeney, Inc. (US) 2012-03-20 US disclosed
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation ANGIOGENEX 2009-09-10 US disclosed
WO-1996034866-A1 IMIDAZO 1,2-A PYRIDINE AND IMIDAZO 1,2-A PYRIDEZINE DERIVATIVES AND THEIR USE AS BONE RESORPTION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-11-07 WO disclosed
CN-1077707-A The method for preparing p-aminophenol RHONE POULENC CHIMIE (FR) 1993-10-27 CN disclosed
US-4296128-A ANTITHROMBOSIS AGENTS CIBA-GEIGY CORPORATION (US) 1981-10-20 US disclosed
EP-0019587-A1 Carboxylic acid hydrazides, process for their preparation, their use and pharmaceutical compositions containing them CIBA-GEIGY AG (CH) 1980-11-26 EP disclosed
US-4179439-A Rifamycins and method for their preparation INTREPRINDEREA DE ANTIBIOTICE IASI (RO) 1979-12-18 US disclosed
US-4150139-A MUSCLE RELAXANTS, ANALGESICS, ANTIINFLAMMATORY TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1979-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation BRAF, MAPK1, RAF1 RAB9A 1023/4885SMN1; SMN2 3141/4885NAPRT 3518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.